1. Home
  2. AEC vs MAIA Comparison

AEC vs MAIA Comparison

Compare AEC & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anfield Energy Inc.

AEC

Anfield Energy Inc.

HOLD

Current Price

$4.76

Market Cap

72.8M

Sector

Real Estate

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.41

Market Cap

79.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEC
MAIA
Founded
1989
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.8M
79.0M
IPO Year
2011
2022

Fundamental Metrics

Financial Performance
Metric
AEC
MAIA
Price
$4.76
$1.41
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
42.6K
323.3K
Earning Date
05-01-2015
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.66
$0.87
52 Week High
$12.49
$3.19

Technical Indicators

Market Signals
Indicator
AEC
MAIA
Relative Strength Index (RSI) 52.56 52.18
Support Level $4.04 $1.36
Resistance Level $5.11 $1.46
Average True Range (ATR) 0.27 0.05
MACD 0.03 0.00
Stochastic Oscillator 58.05 37.93

Price Performance

Historical Comparison
AEC
MAIA

About AEC Anfield Energy Inc.

Anfield Energy Inc is a mineral exploration and development company. This company focuses on uranium and vanadium development and near-term production. The exploration project of the company includes Shootaring Canyon Mill and Velvet-Wood and Slick Rock Uranium Project from Uranium One and The West Slope Project located in Montrose and San Miguel Counties in southwestern Colorado. The company's geographical segments are Canada and the United States.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: